Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset And Announces Corporate Name Change To Tharimmune; Stock To Trade On Nasdaq Under "THAR" Effective Sept. 25
Portfolio Pulse from Benzinga Newsdesk
Hillstream BioPharma is planning to acquire a clinical stage asset and has announced a corporate name change to Tharimmune. The company's stock will trade on Nasdaq under the ticker 'THAR' effective from September 25, 2023. Tharimmune also expects to launch and complete a Phase 1 trial in Q4 2023.
September 22, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hillstream BioPharma, now Tharimmune, is acquiring a clinical stage asset and will trade under the new ticker 'THAR' from Sept 25, 2023. A Phase 1 trial is expected in Q4 2023.
The acquisition of a clinical stage asset and the name change to Tharimmune could potentially attract new investors and increase the company's visibility in the market. The announcement of a Phase 1 trial in Q4 2023 also indicates progress in the company's pipeline, which could positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100